Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use.
This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.